Matthew Winton
CIK 1971400 · Chief Commercial and Business · last filed 2026-02-13
Matthew Winton is a Chief Commercial and Business who has filed 12 SEC Form 4 insider transactions across 2 companies since 2023. The most recent filing, for CRVO, was dated Feb 13, 2026. Across all open-market trades the lifetime net is +$117.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $36.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$36.8K
2
12
$117.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRVO | Chief Commercial and Business | 15,000 | $2.45 | $36.8K | $117.1K | 4 | 2026-02-13 |
| Inozyme Pharma, Inc. (INZY) Delisted | COO | 21,743 | $4.00 | $87.0K | $0 | 7 | 2025-06-27 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-13 | CRVO | Grant (A) | — | $0 | EDGAR |
| 2025-11-19 | CRVO | Buy (P) | +5,000 | $41.4K | EDGAR |
| 2025-11-17 | CRVO | Buy (P) | +10,000 | $75.7K | EDGAR |
| 2025-10-08 | CRVO | Grant (A) | — | $0 | EDGAR |
| 2025-07-03 | — | Mixed | −21,743 | -$87.0K | |
| 2025-06-27 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +14,355 | $10.6K | EDGAR |
| 2025-04-02 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +2,490 | $1.9K | EDGAR |
| 2025-03-17 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-10-03 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +1,710 | $7.6K | EDGAR |
| 2024-04-03 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | +3,188 | $10.6K | EDGAR |